CoChat
Sign Up
Cited by 104Lung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence

Open access
Troiani, Teresa, Napolitano, Stefania, Della Corte, Carminia Maria, Martini, Giulia, Martinelli, Erika, Morgillo, Floriana, Ciardiello, Fortunato·2016·ESMO Open
DOI 10.1136/esmoopen-2016-000088PMC PMC5070253
Open this paper in CoChat — free account

Abstract

Epidermal growth factor receptor (EGFR) plays a key role in tumour evolution, proliferation and immune evasion, and is one of the most important targets for biological therapy, especially for non-small-cell lung cancer (NSCLC) and colorectal cancer (CRC). In the past 15 years, several EGFR antagonists have been approved for the treatment of NSCLC and metastatic CRC (mCRC). To optimise the use of anti-EGFR agents in clinical practice, various clinical and molecular biomarkers have been investigated, thus moving their indication from unselected to selected populations. Nowadays, anti-EGFR drugs represent a gold-standard therapy for metastatic NSCLC harbouring EGFR activating mutation and for RAS wild-type mCRC. Their clinical efficacy is limited by the presence of intrinsic resistance or the onset of acquired resistance. In this review, we provide an overview of the antitumour activity of EGFR inhibitors in NSCLC and CRC and of mechanisms of resistance, focusing on the development of a personalised approach through 15 years of preclinical and clinical research.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/esmoopen-2016-000088

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The differential activity of EGFR inhibitors in CRC versus NSCLC further indicates signaling differences in these two lineages.

    “Moreover, the differential activity of EGFR inhibitors in CRC versus NSCLC further indicate signaling differences in these two lineages(33).”

    From EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. (2020) · cites this paper as [33]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 73

  1. [1]Ciardiello F, Tortora G EGFR antagonist in cancer treatment. N Engl J Med 2008; 358: 1160– 74. 10.1056/NEJMra0707704 18337605 · DOI
  2. [2]Siegel RL, Miller KD, Jemal A Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7– 30. 10.3322/caac.21332 26742998 · DOI · Paper page
  3. [3]Schiller JH, Harrington D, Belani CP Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92– 8. 10.1056/NEJMoa011954 11784875 · DOI · Paper page
  4. [5]Mendelsohn J, Prewett M, Rockwell P CCR 20th anniversary commentary: a chimeric antibody, C225, inhibits EGFR activation and tumor growth. Clin Cancer Res 2015; 21: 227– 9. 10.1158/1078-0432.CCR-14-2491 25593342 · DOI
  5. [6]Baselga J, Pfister D, Cooper MR Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18: 904– 14. 10673534
  6. [7]Robert F, Ezekiel MP, Spencer SA Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J ClinOncol 2001; 19: 3234– 43. 11432891
  7. [8]Foon KA, Yang XD, Weiner LM Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004; 58: 984– 90. 10.1016/j.ijrobp.2003.09.098 14967460 · DOI
  8. [9]Normanno N, Bianco C, De Luca A Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003; 10: 1– 21. 10.1677/erc.0.0100001 12653668 · DOI
  9. [10]Saltz LB, Meropol NJ, Loehrer PJ Sr Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201– 8. 10.1200/JCO.2004.10.182 14993230 · DOI · Paper page
  10. [11]Van Cutsem E, Peeters M, Siena S Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658– 64. 10.1200/JCO.2006.08.1620 17470858 · DOI · Paper page
  11. [12]Cunningham D, Humblet Y, Siena S Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337– 45. 10.1056/NEJMoa033025 15269313 · DOI · Paper page
  12. [14]Peeters M, Price TJ, Cervantes A Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 4706– 13. 10.1200/JCO.2009.27.6055 20921462 · DOI · Paper page
  13. [15]Seymour MT, Brown SR, Middleton G Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013; 14: 749– 59. 10.1016/S1470-2045(13)70163-3 23725851 PMC3699713 · DOI
  14. [16]Sobrero AF, Maurel J, Fehrenbacher L EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 2311– 9. 10.1200/JCO.2007.13.1193 18390971 · DOI
  15. [18]Tabernero J, Van Cutsem E, Díaz-Rubio E Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007; 25: 5225– 32. 10.1200/JCO.2007.13.2183 18024868 · DOI · Paper page
  16. [19]Van Cutsem E, Lenz HJ, Köhne CH Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 2015; 33: 692– 700. 10.1200/JCO.2014.59.4812 25605843 · DOI · Paper page
  17. [20]Maughan TS, Adams RA, Smith CG Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103– 14. 10.1016/S0140-6736(11)60613-2 21641636 PMC3159415 · DOI · Paper page
  18. [21]Tveit KM, Guren T, Glimelius B Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012; 30: 1755– 62. 10.1200/JCO.2011.38.0915 22473155 · DOI
  19. [22]Douillard JY, Siena S, Cassidy J Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated meta-static colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697– 705. 10.1200/JCO.2009.27.4860 20921465 · DOI
  20. [23]Douillard JY, Oliner KS, Siena S Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023– 34. 10.1056/NEJMoa1305275 24024839 · DOI · Paper page
  21. [24]Zhang Y, Sheng J, Yang Y Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network metanalysis. Oncotarget 2016; 7: 20093– 108. 10.18632/oncotarget.7713 26933807 PMC4990517 · DOI
  22. [26]Mitsudomi T, Kosaka T, Endoh H Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 2513– 20. 10.1200/JCO.2005.00.992 15738541 · DOI
  23. [28]Giaccone G, Herbst RS, Manegold C Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1. J Clin Oncol 2004; 22: 777– 84. 10.1200/JCO.2004.08.001 14990632 · DOI
  24. [29]Herbst RS, Giaccone G, Schiller JH Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. J Clin Oncol 2004; 22: 785– 94. 10.1200/JCO.2004.07.215 14990633 · DOI
  25. [31]Gatzemeier U, Pluzanska A, Szczesna A Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25: 1545– 52. 10.1200/JCO.2005.05.1474 17442998 · DOI
  26. [32]Shepherd FA, Rodrigues Pereira J, Ciuleanu T Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123– 32. 10.1056/NEJMoa050753 16014882 · DOI · Paper page
  27. [34]Mitsudomi T, Morita S, Yatabe Y Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol 2010; 11: 121– 8. 10.1016/S1470-2045(09)70364-X 20022809 · DOI · Paper page
  28. [35]Maemondo M, Inoue A, Kobayashi K Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380– 8. 10.1056/NEJMoa0909530 20573926 · DOI · Paper page
  29. [36]Zhou C, Wu YL, Chen G Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomized, phase 3 study. Lancet Oncol 2011; 12: 735– 42. 10.1016/S1470-2045(11)70184-X 21783417 · DOI · Paper page
  30. [37]Rosell R, Carcereny E, Gervais R Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol 2012; 13: 239– 46. 10.1016/S1470-2045(11)70393-X 22285168 · DOI · Paper page
  31. [38]Li D, Ambrogio L, Shimamura T BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008; 27: 4702– 11. 10.1038/onc.2008.109 18408761 PMC2748240 · DOI · Paper page
  32. [39]Yang JC, Shih JY, Su WC Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012; 13: 539– 48. 10.1016/S1470-2045(12)70086-4 22452895 · DOI
  33. [43]Schwartzberg LS, Rivera F, Karthaus M PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014; 32: 2240– 7. 10.1200/JCO.2013.53.2473 24687833 · DOI
  34. [44]Ciardiello F, Normanno N, Maiello E Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. Ann Oncol 2014; 25: 1756– 61. 10.1093/annonc/mdu230 24942275 · DOI · Paper page
  35. [45]Ciardiello F, Normanno N, Martinelli E Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. Ann Oncol 2016; 27: 1055– 61. 10.1093/annonc/mdw136 27002107 · DOI
  36. [48]Sorich MJ, Wiese MD, Rowland A Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 2015; 26: 13– 21. 10.1093/annonc/mdu378 25115304 · DOI
  37. [49]Heinemann V, von Weikersthal LF, Decker T FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1065– 75. 10.1016/S1470-2045(14)70330-4 25088940 · DOI · Paper page
  38. [50]Han JY, Park K, Kim SW First-signal: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never- smokers with adenocarcinoma of the lung. J Clin Oncol 2012; 30: 1122– 8. 10.1200/JCO.2011.36.8456 22370314 · DOI · Paper page
  39. [51]LeCaer H, Greillier L, Corre R A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study). Lung Cancer 2012; 77: 97– 103. 10.1016/j.lungcan.2012.02.004 22405570 · DOI
  40. [52]Troiani T, Martinelli E, Napolitano S Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. Curr Med Chem 2014; 21: 1639– 53. 10.2174/09298673113209990224 23992332 · DOI
  41. [53]Manzo A, Della Corte CM, Festino L Management of EGFR-mutant non-small-cell lung cancer patients after first-line reversible EGF receptor-tyrosine kinase inhibitors. Future Medicine 2014; 3: 77– 84.
  42. [55]De Roock W, Claes B, Bernasconi D Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753– 62. 10.1016/S1470-2045(10)70130-3 20619739 · DOI · Paper page
  43. [56]Sartore-Bianchi A, Martini M, Molinari F PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009; 69: 1851– 7. 10.1158/0008-5472.CAN-08-2466 19223544 · DOI · Paper page
  44. [58]Bardelli A, Corso S, Bertotti A Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013; 3: 658– 73. 10.1158/2159-8290.CD-12-0558 23729478 PMC4078408 · DOI · Paper page
  45. [59]Smith G, Bounds R, Wolf H Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours -implications for personalised cancer medicine. Br J Cancer 2010; 102: 693– 703. 10.1038/sj.bjc.6605534 20147967 PMC2837563 · DOI
  46. [60]Misale S, Yaeger R, Hobor S Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532– 6. 22722830 PMC3927413
  47. [62]Scartozzi M, Mandolesi A, Giampieri R The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. Oncologist 2011; 16: 53– 60. 10.1634/theoncologist.2010-0119 21212430 PMC3228051 · DOI
  48. [63]Scartozzi M, Mandolesi A, Giampieri R Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. Int J Cancer 2010; 127: 1941– 7. 10.1002/ijc.25193 20099280 · DOI · Paper page
  49. [64]Klughammer B, Brugger W, Cappuzzo F Examining treatment outcomes with erlotinib in patients with advanced non-small cell lung cancer whose tumors harbor uncommon EGFR mutations. J Thorac Oncol 2016; 11: 545– 55. 10.1016/j.jtho.2015.12.107 26773740 · DOI · Paper page
  50. [66]Godin-Heymann N, Bryant I, Rivera MN Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res 2007; 67: 7319– 26. 10.1158/0008-5472.CAN-06-4625 17671201 PMC2882853 · DOI
  51. [67]Lou Y, Pecot CV, Tran HT Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. Clin Lung Cancer 2016; 17: e5– e11. 10.1016/j.cllc.2015.11.003 26700910 PMC5119523 · DOI
  52. [70]Normanno N, Tejpar S, Morgillo F Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009; 6: 519– 27. 10.1038/nrclinonc.2009.111 19636327 · DOI · Paper page
  53. [72]Arena S, Bellosillo B, Siravegna G Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin Cancer Res 2015; 21: 2157– 66. 10.1158/1078-0432.CCR-14-2821 25623215 · DOI · Paper page
  54. [76]Pietrantonio F, Petrelli F, Coinu A Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 2015; 51: 587– 94. 10.1016/j.ejca.2015.01.054 25673558 · DOI · Paper page
  55. [77]Troiani T, Napolitano S, Vitagliano D Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. Clin Cancer Res 2014; 20: 3775– 86. 10.1158/1078-0432.CCR-13-2181 24812410 · DOI · Paper page
  56. [78]Morgillo F, Cascone T, D'Aiuto E Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors. Br J Cancer 2011; 105: 382– 92. 10.1038/bjc.2011.244 21750552 PMC3172903 · DOI
  57. [79]Chen JY, Cheng YN, Han L Predictive value of K-RAS and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis. Cancer Biol Med 2015; 12: 126– 39. 10.7497/j.issn.2095-3941.2015.0021 26175928 PMC4493374 · DOI
  58. [80]Tural D, Batur S, Erdamar S Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS. Tumour Biol 2014; 35: 1041– 9. 10.1007/s13277-013-1138-8 23996432 · DOI
  59. [81]Montagut C, Dalmases A, Bellosillo B Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat Med 2012; 18: 221– 3. 10.1038/nm.2609 22270724 · DOI · Paper page
  60. [82]Kobayashi S, Boggon TJ, Dayaram T EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786– 92. 10.1056/NEJMoa044238 15728811 · DOI · Paper page
  61. [83]Jänne PA, Yang JC, Kim DW AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015; 372: 1689– 99. 10.1056/NEJMoa1411817 25923549 · DOI · Paper page
  62. [84]Bean J, Riely GJ, Balak M Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 2008; 14: 7519– 25. 10.1158/1078-0432.CCR-08-0151 19010870 PMC2596620 · DOI
  63. [85]Yonesaka K, Zejnullahu K, Okamoto I Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011; 3: 99ra86 10.1126/scitranslmed.3002442 21900593 PMC3268675 · DOI · Paper page
  64. [86]Sartore-Bianchi A, Trusolino L, Martino C Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER-2positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016; 17: 738– 46. 10.1016/S1470-2045(16)00150-9 27108243 · DOI · Paper page
  65. [87]Tol J, Nagtegaal ID, Punt CJ BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361: 98– 9. 10.1056/NEJMc0904160 19571295 · DOI
  66. [89]Pedersen MW, Jacobsen HJ, Koefoed K Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010; 70: 588– 97. 10.1158/0008-5472.CAN-09-1417 20068188 · DOI
  67. [90]Dienstmann R, Patnaik A, Garcia-Carbonero R Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer. Cancer Discov 2015; 5: 598– 609. 10.1158/2159-8290.CD-14-1432 25962717 · DOI · Paper page
  68. [92]Kearns JD, Bukhalid R, Sevecka M Enhanced targeting of the EGFR network with MM-151, an oligoclonal anti-EGFR antibody therapeutic. Mol Cancer Ther 2015; 14: 1625– 36. 10.1158/1535-7163.MCT-14-0772 25911688 · DOI
  69. [93]Arena S, Siravegna G, Mussolin B MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Sci Transl Med 2016; 8: 324ra14 10.1126/scitranslmed.aad5640 26843189 · DOI · Paper page
  70. [94]Lieu CH, Beeram M, Harb WA Safety, pharmacology, and preliminary clinical activity of MM-151: an oligocolnal anti-EGFR therapeutic in patients with cetuximab-resistant CRC and other refractory solid tumors. J Clin Oncol 2015; 33: 647.
  71. [95]Costa DB, Kobayashi SS Whacking a molecule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M. Transl Lung Cancer Res 2015; 4: 809– 15. 10.3978/j.issn.2218-6751.2015.05.05 26798593 PMC4700227 · DOI
  72. [96]Thress KS, Paweletz CP, Felip E Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 2015; 21: 560– 2. 10.1038/nm.3854 25939061 PMC4771182 · DOI · Paper page
  73. [97]Siravegna G, Mussolin B, Buscarino M Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 2015; 21: 827 10.1038/nm0715-827b 26151329 · DOI

Cited by

Sorted by citations

Authors
Troiani, T., Napolitano, S., Della Corte, C. M., Martini, G., Martinelli, E., Morgillo, F., & Ciardiello, F.
Affiliations
University of Campania "Luigi Vanvitelli" (IT)
Corresponding author
Troiani, Teresa
ORCID
Venue
ESMO Open
Publisher
Elsevier BV
Published
2016
Volume
1
Issue
5
Pages
e000088
ISSN
2059-7029 (ISSN-L)
DOI
10.1136/esmoopen-2016-000088
PMC
PMC5070253
OpenAlex
W2531651639
Cited by
104
References
22
Citations by year
2026: 1 · 2025: 4 · 2024: 8 · 2023: 9 · 2022: 10 · 2021: 13 · 2020: 19 · 2019: 11 · 2018: 15 · 2017: 14
FWCI
2.31
Type
journal article
Language
en
Open access
Licence
Locations
  • ESMO Open (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion, public-domain)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
EGFR inhibition, epidermal growth factor receptor, non-small cell lung cancer, metastatic colorectal cancer, anti-EGFR therapy, EGFR activating mutations, RAS wild-type, biomarkers, acquired drug resistance, intrinsic resistance, targeted therapy, personalized medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review